908 Devices SVP reports initial share holdings
908 Devices Inc. executive John Kenneweg, SVP of Sales & Product Marketing, filed an initial Form 3 detailing his equity holdings in the company.
Rhea-AI Filing Summary
908 Devices Inc. executive John Kenneweg, SVP of Sales & Product Marketing, filed an initial Form 3 detailing his equity holdings in the company. The filing shows multiple stock option awards and restricted stock units, along with 57,784 shares of Common Stock held directly as of February 26, 2026.
Footnotes describe how various option grants and RSUs vest over time, with portions having already vested and remaining amounts vesting in monthly or annual installments through 2027, subject to his continued service. All entries are reported as holdings, with no explicit purchases or sales indicated in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
14 transactions reported
Mixed
14 txns
Insider
Kenneweg John
Role
SVP, Sales & Product Marketing
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 297,038 contracts (Direct);
Restricted Stock Units — 129,693 contracts (Direct);
Common Stock — 57,784 shares (Direct)
Footnotes (9)
- F1. The shares underlying the option are fully vested and immediately exercisable.
- F2. Twenty-five percent of the shares underlying the option became vested and exercisable on February 1, 2024, and the remaining 75% of the shares underlying the option became or will become vested and exercisable in substantially equal monthly installments over the 36 months following February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.
- F3. Twenty-five percent of the shares underlying the option became vested and exercisable on February 1, 2025, and the remaining 75% of the shares underlying the option became or will become vested and exercisable in substantially equal monthly installments over the 36 months following February 1, 2025, subject to the reporting person's continued service through the applicable vesting date.
- F4. One-third of the shares underlying the option became vested and exercisable on February 1, 2026, and the remaining two-thirds of the shares underlying the option became or will become vested and exercisable in substantially equal monthly installments over the 24 months following February 1, 2026, subject to the reporting person's continued service through the applicable vesting date.
- F5. One-third of the shares underlying the option become vested and exercisable on February 1, 2027, and the remaining two-thirds of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 24 months following February 1, 2027, subject to the reporting person's continued service through the applicable vesting date.
- F6. These restricted stock units ("RSUs") vest on February 1, 2027, subject to the reporting person's continued service through the applicable vesting date. The RSUs have no expiration date.
- F7. Each RSU represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
- F8. These RSUs vest in two substantially equal annual installments at the two anniversary dates following February 1, 2026, subject to the reporting person's continued service through the applicable vesting date. The RSUs have no expiration date.
- F9. These RSUs vest in three substantially equal annual installments at the three anniversary dates following February 1, 2026, subject to the reporting person's continued service through the applicable vesting date. The RSUs have no expiration date.
FAQ
What does the 908 Devices (MASS) Form 3 for John Kenneweg report?
The Form 3 reports John Kenneweg’s initial beneficial ownership in 908 Devices, including stock options, restricted stock units, and 57,784 directly held common shares as of February 26, 2026, plus detailed vesting schedules extending through 2027 tied to his continued service.
What equity awards are disclosed for John Kenneweg in 908 Devices (MASS) Form 3?
The Form 3 discloses multiple stock option awards and several restricted stock unit grants for John Kenneweg. These awards vest over time, with portions already vested and remaining tranches scheduled to vest in monthly or annual installments through 2027, assuming he continues in service.
How do John Kenneweg’s stock options at 908 Devices (MASS) vest?
The stock option footnotes state that some grants vested 25% or one-third on specific February 1 dates, with remaining shares vesting in substantially equal monthly installments over 24 or 36 months, extending through 2026 and 2027, conditioned on his continued service with 908 Devices.
What are the vesting terms for John Kenneweg’s RSUs at 908 Devices (MASS)?
The RSU footnotes explain that some restricted stock units vest fully on February 1, 2027, while others vest in two or three substantially equal annual installments following February 1, 2026. Each RSU converts into one share of common stock upon vesting and has no expiration date.
Does the 908 Devices (MASS) Form 3 show insider stock purchases or sales?
The Form 3 lists John Kenneweg’s holdings in stock options, restricted stock units, and common stock, but does not report explicit purchases or sales. All transaction entries are characterized as holdings, reflecting his beneficial ownership position rather than new buy or sell activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
